

IDEXX LABORATORIES INC /DE
Form 8-K
July 25, 2014

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): July 21, 2014

IDEXX LABORATORIES, INC.

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction

of incorporation)

000-19271
(Commission

File Number)

01-0393723
(IRS Employer

Identification No.)

One IDEXX Drive, Westbrook, Maine
(Address of principal executive offices)

04092
(ZIP Code)

207.556.0300

(Registrant's telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. to Form 8-K):

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 1.01 Entry into a Material Definitive Agreement.
Prudential Agreement

On July 21, 2014, IDEXX Laboratories, Inc. (the Company) issued and sold through a private placement an aggregate principal amount of \$125,000,000 of senior notes consisting of \$50,000,000 of 3.32% Series A Senior Notes due July 21, 2021 (the 2021 Notes) and \$75,000,000 of 3.76% Series B Senior Notes due July 21, 2024 (the 2024 Notes) under a Note Purchase and Private Shelf Agreement among the Company, Prudential Investment Management, Inc. (Prudential) and the accredited institutional purchasers named therein (the Prudential Agreement). The Company will use the net proceeds from the 2021 Note and the 2024 Notes for general corporate purposes, including repaying amounts outstanding under its revolving credit facility.

The Prudential Agreement also provides for an uncommitted shelf facility by which the Company may request that Prudential purchase, over the next three years, up to \$175,000,000 million of additional senior promissory notes of the Company at a fixed interest rate and with a maturity date not to exceed twelve years (the Shelf Notes and together with the 2021 Notes and the 2024 Notes, the Prudential Notes). Prudential is under no obligation to purchase any of the Shelf Notes. The interest rate of any series of Shelf Notes will be determined at the time of purchase. The proceeds of any series of Shelf Notes will be used as specified in the request for purchase with respect to such series, subject to compliance with the requirement in the Prudential Agreement that the proceeds of the Prudential Notes will be used only for general corporate purposes.

The 2021 Notes bear interest at a fixed rate of 3.32% and mature on July 21, 2021. The 2024 Notes bear interest at a fixed rate of 3.76% and mature on July 21, 2024. The Company may prepay any series of the Prudential Notes in an amount not less than \$1,000,000 (and otherwise in multiples of \$100,000) of such series of Prudential Notes then outstanding at 100% of the principal amount so prepaid, plus the applicable make-whole amount (as set forth in the Prudential Agreement) upon no more than 60 or less than 10 days' written notice to the holders of the Prudential Notes. In addition, in the event of a change in control (as defined in the Prudential Agreement) of the Company or upon the disposition of certain assets of the Company the proceeds of which are not reinvested (as set forth in the Prudential Agreement), at the option of the holders of the Prudential Notes, the Company may be required to prepay all or a portion of the Prudential Notes at a price equal to 100% of the principal amount thereof, plus accrued and unpaid interest.

The obligations of the Company under the Prudential Notes may be accelerated upon the occurrence of an event of default under the Prudential Agreement, which includes customary events of default including, without limitation, payment defaults, defaults in the performance of affirmative and negative covenants, the inaccuracy of representations or warranties, bankruptcy and insolvency related defaults, defaults relating to judgments, an ERISA event and the failure to pay specified indebtedness.

The Prudential Agreement contains affirmative, negative and financial covenants customary for agreements of this type. The negative covenants include restrictions on liens, indebtedness of subsidiaries of the Company, priority indebtedness, fundamental changes, investments, transactions with affiliates, certain restrictive agreements and violations of laws and regulations. The financial covenant is a consolidated leverage ratio test. The obligations of the Company under the Prudential Notes are unconditionally guaranteed by IDEXX Distribution, Inc., IDEXX Operations, Inc., IDEXX Reference Laboratories, Inc. and OPTI Medical Systems, Inc. The Company also must add any subsidiary as a guarantor under the Prudential Notes if such subsidiary becomes liable with the Company for or in respect of any indebtedness of the Company under a material credit facility (but excluding any foreign subsidiary that does not guarantee indebtedness of the Company or any US subsidiaries under a material credit facility).

The foregoing description of the Prudential Agreement is qualified in its entirety by reference to the Prudential Agreement, a copy of which is filed as Exhibit 99.1 hereto and incorporated herein by this reference.

NYL Agreement

On July 22, 2014, the Company entered into a Note Purchase Agreement among the Company and the accredited institutional purchasers named therein (the "NYL Agreement") pursuant to which the Company agreed to issue and sell \$75,000,000 of its 3.72% Senior Notes having a twelve-year term (the "2026 Notes") at a purchase price of 100% of the principal amount of the 2026 Notes. The issuance, sale and purchase of the 2026 Notes are subject to the satisfaction of standard closing conditions for private placement term note transactions, and the Company expects that the issuance, sale and purchase of the 2026 Notes will close in September 2014. The accredited institutional investors that are a party to the NYL Agreement also purchased the Company's 3.94% Series A Senior Notes due December 11, 2023, which were issued and sold by the Company to such investors on December 11, 2013 in a private placement transaction. The Company intends to use the net proceeds from the issuance and sale of the 2026 Notes pursuant to the NYL Agreement for general corporate purposes, including repaying amounts outstanding under its revolving credit facility.

If and when issued, the 2026 Notes will bear interest at a fixed rate of 3.72% and mature twelve years after the original issuance date. In addition, the Company may prepay the 2026 Notes, if and when issued, in an amount not less than 5.0% of the aggregate principal amount of the 2026 Notes then outstanding at 100% of the principal amount so prepaid, plus the applicable make-whole amount (as set forth in the NYL Agreement) upon no more than 60 or less than 10 days' written notice to the holders of the 2026 Notes. In addition, if and when the 2026 Notes are issued, in the event of a change in control (as defined in the NYL Agreement) of the Company or upon the disposition of certain assets of the Company the proceeds of which are not reinvested (as set forth in the NYL Agreement), at the option of the holders of the 2026 Notes, the Company may be required to prepay all or a portion of the 2026 Notes at a price equal to 100% of the principal amount thereof, plus accrued and unpaid interest.

If and when the 2026 Notes are issued, the obligations of the Company under the 2026 Notes may be accelerated upon the occurrence of an event of default under the NYL Agreement, which includes customary events of default including, without limitation, payment defaults, defaults in the performance of affirmative and negative covenants, the inaccuracy of representations or warranties, bankruptcy and insolvency related defaults, defaults relating to judgments, an ERISA event and the failure to pay specified indebtedness.

The NYL Agreement contains affirmative, negative and financial covenants customary for agreements of this type. The negative covenants include restrictions on liens, indebtedness of subsidiaries of the Company, priority indebtedness, fundamental changes, investments, transactions with affiliates, certain restrictive agreements and violations of laws and regulations. The financial covenant is a consolidated leverage ratio test. If and when the 2026 Notes are issued, the obligations of the Company will be unconditionally guaranteed by IDEXX Distribution, Inc., IDEXX Operations, Inc., IDEXX Reference Laboratories, Inc. and OPTI Medical Systems, Inc., and the Company will be required to add any subsidiary as a guarantor under the 2026 Notes if such subsidiary becomes liable with the Company for or in respect of any indebtedness of the Company under a material credit facility (but excluding any foreign subsidiary that does not guarantee indebtedness of the Company or any US subsidiaries under a material credit facility).

The foregoing description of the NYL Agreement is qualified in its entirety by reference to the NYL Agreement, which is filed as Exhibit 99.2 hereto and incorporated herein by this reference.

Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of the Registrant.

The disclosure under Item 1.01 is incorporated herein by this reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

See Exhibit Index attached hereto.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

IDEXX LABORATORIES, INC.

Date: July 25, 2014

By: /s/ Jeffrey A. Fiarman
Jeffrey A. Fiarman
Executive Vice President, General Counsel and
Secretary

EXHIBIT INDEX

Exhibit No.	Description of Exhibit
99.1	Note Purchase and Private Shelf Agreement, dated as of July 21, 2014, among the Company, as issuer, Prudential Investment Management, Inc., Pruco Life Insurance Company, The Prudential Insurance Company of America, Prudential Investment Japan Co., Ltd., as investment manager, and Prudential Investment Management, Inc., as sub-adviser for The Gibraltar Life Insurance Co., Ltd., Prudential Arizona Reinsurance Universal Company, as grantor, and Prudential Investment Management, Inc., as investment manager for PAR U Hartford Life Insurance Comfort Trust, Prudential Private Placement Investors, L.P., as investment advisor, and Prudential Private Placement Investors, Inc., as general partner to each of, The Independent Order of Foresters, Zurich American Insurance Company, Globe Life and Accident Insurance Company, Family Heritage Life Insurance Company of America, MTL Insurance Company, The Lincoln National Life Insurance Company, William Penn Life Insurance Company of New York, Farmers Insurance Exchange and Mid Century Insurance Company, as purchasers.
99.2	Note Purchase Agreement, dated as of July 22, 2014, among the Company, as issuer, New York Life Insurance Company, and NYL Investors LLC, as investment manager for New York Life Insurance and Annuity Corporation and New York Life Insurance and Annuity Corporation Institutionally Owned Life Insurance Separate Account (BOLI 30C), as purchasers.